Saturday,
April 29
8:00am–11:00am
2100—Adult Stem Cells—A Primer for the
Clinician
PAS/ASPHO Mini Course
Room 3014, Moscone West
Chairs: Jakub Tolar, University of Minnesota, Minneapolis, MN;
and Mervin C. Yoder, Jr., Indiana University School of
Medicine, Indianapolis, IN
Target Audience:
Hematologists/oncologists, endocrinologists, basic scientists
and neurologists.
Adult stem cells represent a
technology that is being intensively investigated currently,
and this research may have wide implications for human health.
This mini course will focus on recent research and potential
applications in human health.
-
Introduction
Jakub Tolar, University of Minnesota, Minneapolis, MN
Mervin C. Yoder, Indiana
University School of Medicine, Indianapolis, IN
-
Multipotent Adult Progenitor
Cell: Hype or Reality?
Catherine M. Verfaillie, University of Minnesota, Minneapolis, MN
-
Mesenchymal Stem Cell: Harnessing
the Power of Adult Stem Cells To Repair Tissues
Darwin Prockop, Tulane University Health Science Center, New Orleans,
LA
-
Hierarchy of Endothelial
Progenitors in Human Blood and Blood Vessels
David A. Ingram, Indiana University School of Medicine, Indianapolis,
IN
-
Cancer Stem Cell: Concept of
Human Leukemic Development
Craig T. Jordan, James P. Wilmot Cancer Center, University of Rochester
School of Medicine, Rochester, NY
Sponsored jointly by
the American Society of Pediatric Hematology/Oncology and the
Pediatric Academic Societies
8:00am–11:00am
2130—Newborn Hearing Screening: From the
Bedside to Beyond
PAS/PIDS Mini Course
Room 3010, Moscone West
Chairs: Mark R. Schleiss and Lisa Ann Schimmenti, University
of Minnesota Medical School, Minneapolis, MN
Target Audience: General
pediatricians, geneticists and infectious disease specialists.
Sensorineural hearing loss (SNHL)
in infants is the most common birth defect, and early
detection improves outcome. Evidence from the CDC reveals that
less than one half of screened babies are followed up. One
possible reason is the low positive predictive value of
bedside screening. There is a critical need to augment current
strategies to prevent late diagnosis of SNHL. One solution is
to propose second-tier testing for the most common causes of
SNHL, as the most common causes of newborn hearing loss are
infectious and genetic. Of infectious causes, cytomegalovirus
(CMV) is the most common. Evidence of CMV infection can be
found in 1% of newborns, with 10–15% developing hearing loss
or other CNS abnormalities. Of the genetic causes, mutations
in GJB2/GJB6 are the most common and are identified in up to
one half of individuals with SNHL. The goal of this program
will be to examine evidence for inclusion of infectious and
genetic screening to augment current newborn screening
protocols.
-
Diagnostic Evaluation and
Management of Childhood Hearing Loss
Margaret Alene Kenna, Children's Hospital Boston, Boston, MA
-
Range of Mutations in
GJB2-Associated Hearing Loss
Lisa Ann Schimmenti, University of Minnesota Medical School,
Minneapolis, MN
-
Congenital Cytomegalovirus
Infection and Hearing Loss
Karen B. Fowler, University of Alabama at Birmingham, Birmingham, AL
-
Newborn Hearing Screening:
Audiologic Assessment
Yvonne Sininger, University of California Los Angeles, Los Angeles, CA
Sponsored jointly by
the Pediatric Infectious Diseases Society and the Pediatric
Academic Societies
8:00am–12:00pm
2180A—LWPES Plenary Session I
LWPES Plenary Session
Room 3007-3009, Moscone West
Chairs: Lynne Levitsky, Massachusetts General Hospital,
Boston, MA; Henry Anhalt, Saint Barnabas Medical Center,
Livingston, NJ; and Alan D. Rogol, University of Virginia,
Charlottesville, VA
Target Audience:
Endocrinologists, nephrologists, cardiologists, general
pediatricians, immunologists, geneticists and molecular
biologists.
-
Opening Remarks
Lynne L. Levitsky, Massachusetts General Hospital, Boston, MA
-
Lawson Wilkins Lecture:
Recent years have witnessed a
significant revision of the traditional view of fat cells
as simple stores of excess energy. Studies in the
speaker's lab as well as many others have clearly
demonstrated that adipocytes produce and regulate many
metabolic and hormonal signals, which generate profound
effects on systemic endocrine equilibrium. In his earlier
studies, he also demonstrated that these cells exhibit an
inflammatory capacity that is abnormal in obesity and key
to the pathogenesis of insulin resistance and diabetes.
Recently, he identified a key molecular mechanism
underlying the link between inflammatory responses and
insulin action. This pathway involves obesity-related
activation of the serine, threonine kinase, JNK, and the
consequent inhibition of insulin receptor signaling via
phosphorylation of a substrate of insulin receptor, IRS-1.
-
Integration of Metabolic and
Inflammatory Pathways in Metabolic Disease
Gokhan S. Hotamisligil, Harvard School of Public Health, Boston, MA
-
Robert Blizzard Lecture:
One of the greatest questions
asked of physicians caring for children with autoimmune
diabetes is "why did this happen?" This session
will unravel some of the mysteries surrounding the
etiology and pathogenesis of autoimmune diabetes from an
investigator who has dedicated his life to this issue.
-
On the Unravelling of the
Etiopathogenesis of Type 1 Diabetes: Are We Stuck or
Are We Winning?
Gian Franco Bottazzo, Ospedale Pediatrico Bambino Gesú, Scientific
Institute, Rome, Italy
-
Break
-
Esoterix Lecture:
The attendee will familiarize
him/herself with newer molecular mechanisms of growth
failure that are due to abnormalities in receptor and
post-receptor translation of GH signaling.
-
Molecular Mechanisms and Defects
in Growth Hormone Receptor Signaling
Peter Rotwein, Oregon Health and Science University, Portland, OR
9:00am–11:00am
2196—Modulators of Bronchopulmonary
Dysplasia
PAS Platform Session
Room 3003-3005, Moscone West
Chairs: Suhas G. Kallapur and Lawrence M. Nogee
Supported by an unrestricted educational grant from Dey,
L.P.
12:00pm–3:00pm
2505—Embryonic Stem Cells: A Primer for
Clinicians
PAS Mini Course
Room 3014, Moscone West
Chair: Michael T. Longaker, Stanford University, Stanford, CA
Embryonic stem cells offer
incredible promise for treating diseases affecting both
children and adults. This mini course will provide an overview
of stem cells and a basic understanding of how to derive human
embryonic stem cells, recent research and ethical
considerations. After attending this session, attendee will
have a better understanding of: 1) what are embryonic stem
cells; 2) how human embryonic stem cells are derived; 3)
recent progress in human embryonic stem cell research; 4)
ethical considerations in human embryonic stem cells.
-
Stem Cells: Embryonic, Adult and
Cancer
Michael T. Longaker, Stanford University, Stanford, CA
-
What It Takes Clinically To Get
an Embryonic Stem Cell
Linda C. Giudice, University of California, San Francisco, San
Francisco, CA
-
What Can You Do with an Embryonic
Stem Cell in Research
Renee Reijo Pera, University of California, San Francisco, San
Francisco, CA
-
Ethical and Oversight
Considerations in Human Embryonic Stem Cell Research
Hank Greely, Stanford University, Stanford, CA
-
Panel Discussion
Supported in part by an unrestricted educational grant from
Treuman Katz Center for Pediatric Bioethics - Seattle
Children's Hospital
1:00pm–3:00pm
2610—Genetics and Epigenetics of Neonatal
Disease
PAS Platform Session
Room 3022, Moscone West
Chairs: Aaron Hamvas and Jeffrey C. Murray
1:30pm–3:30pm
2670A—Controversies in Care in Pediatric
Endocrinology—The Great Debates
LWPES Workshop
Room 3001, Moscone West
Chairs: William Clarke, University of Virginia,
Charlottesville, VA; and Henry Anhalt, St. Barnabas Medical
Center, Livingston, NJ
Target Audience:
Endocrinologists, general pediatricians and adolescent
medicine specialists.
The attendee will be part of a
lively debate on a number of areas of controversy in pediatric
state-of-the-art diabetes management.
-
Is Primary Prevention of Type 1
Diabetes Possible?
-
Pro—Desmond A. Schatz, University of Florida, Gainesville, FL
-
Con—Dorothy J. Becker, Children's Hospital of Pittsburgh, Pittsburgh, PA
-
Should Glucose Sensors Be
Routinely Used?
-
Pro—Stuart Alan Weinzimer, Yale School of Medicine, New Haven, CT
-
Con—Darrell M. Wilson, Stanford University Medical Center, Stanford, CA
-
Should Metformin Be Used To Treat
Pediatric Patients with Insulin Resistance?
-
Pro—Michael S. Freemark, Duke University Medical Center, Durham, NC
-
Con—Philip Scott Zeitler, University of Colorado at Denver and Health
Sciences Center, Denver, CO
4:00pm–7:30pm
Commercial Exhibits Open and Posters
Available for Viewing
PAS Exhibits
Levels 1 and 2, Moscone West
Posters Available for Viewing:
4:00pm–7:30pm
Author Attendance: 5:15pm–7:15pm
Level 1:
– Developmental Biology
– Endocrinology
– Hematology–Oncology
– Neonatal Infectious Diseases
– Neonatology
– Nephrology
Level 2:
– Cardiology
– Developmental–Behavioral Pediatrics
– General Pediatrics
– Medical Education
– Neurology
5:15pm–7:15pm
Poster Session I and PAS Opening Reception
PAS Poster Session
Levels 1 and 2, Moscone West
Posters Available for Viewing:
4:00pm–7:30pm
Author Attendance: 5:15pm–7:15pm
Level 1:
– Developmental Biology
– Endocrinology
– Hematology–Oncology
– Neonatal Infectious Diseases
– Neonatology
– Nephrology
Level 2:
– Cardiology
– Developmental–Behavioral Pediatrics
– General Pediatrics
– Medical Education
– Neurology
Includes
-
SPR Student Research Award:
Resuscitation of Non-Viable Infants: Will
Neonatologists[apos] Practice Change After the Born-Alive
Infant Protection Act?
Mya Sendowski, University of California, San Francisco, CA
Sunday,
April 30
8:00am–10:00am
3110—Probiotics in Necrotizing
Enterocolitis—Their Clinical Effect and Possible Mechanisms
PAS/ASPR/JPS/NASPGHAN Topic Symposium
Room 3003-3005, Moscone West
Chairs: W. Allan Walker, Harvard Medical School, Boston, MA;
and Yuichiro Yamashiro, Juntendo University School of
Medicine, Tokyo, Japan
Target Audience: Neonatologists,
gastroenterologists, pediatric surgeons, NICU nurses and
bacteriologists in perinatal medicine.
Necrotizing enterocolitis (NEC)
is a serious gastrointestinal disease seen predominantly in
very low birth weight (VLBW) and extremely low birth weight (ELBW)
infants. NEC is probably a complex, multifactorial disease.
Currently, the precise pathogenic mechanisms remain to be
elucidated; however, clinical use of probiotics has been
reported to be useful for preventing NEC development in VLBW
and ELBW infants. This session will provide us the current
knowledge about the role of probiotics in the management of
NEC.
-
Fifteen-Year's Experience of
Early Administration of Bifidobacterium Breve to Preterm
Infants
H. Kitajima, Osaka Medical Center and Research Institute for Maternal
and Child Health, Osaka, Japan
-
Oral Probiotics Reduces Incidence
of NEC in VLBW Infants
H. C. Lin, China Medical University, Taichung, Taiwan
-
Effects of Probiotics on the
Immunological Development and Short Chain Fatty Acids in
ELBW and VLBW Infants
Yoshikazu Ohtsuka, Juntendo University School of Medicine, Bunkyo-ku,
Japan
-
Possible Role of Probiotic
Supplementation for Prevention from NEC
Michael S. Caplan, Northwestern University, Evanston, IL
Sponsored jointly by
the Asian Society for Pediatric Research; Japan Pediatric
Society; North American Society for Pediatric
Gastroenterology, Hepatology & Nutrition and the Pediatric
Academic Societies
8:00am–10:00am
3115A—Renal Pathology—Its Still Not Just
Little Adults
ASPN Symposium
Room 2003-2005, Moscone West
Chairs: Sharon P. Andreoli, James Whitcomb Riley Hospital for
Children, Indiana University Medical Center, Indianapolis, IN;
and Patrick Walker, Nephropathology Associates
Target Audience: Nephrologists
and pathologists.
The pathologic features of the
kidney in pediatric kidney disease have unique features
compared to adult patients and, some kidney diseases are
solely observed in pediatric patients. This symposia will
address the unique pathologic features of congenital nephrotic
syndrome, MPGN, renal pathology in pediatric transplant
patients and will also propose a new taxonomy for the
podocytopathies.
-
Congenital Nephrotic
Syndrome—An Update
Stephen M. Bonsib, James Whitcomb Riley Hospital for Children, Indiana
University Medical Center, Indianapolis, IN
-
MPGN and Dense Deposit Disease
Patrick D. Walker, Nephropathology Associates, Little Rock, AR
-
Renal Pathology in Pediatric
Transplant Patients
Carole A. Vogler, Saint Louis University, St. Louis, MO
-
Toward a New Taxonomy for the
Podocytopathies
Laura Barisoni, New York University School of Medicine, New York, NY
8:00am–10:00am
3125—Developmental Origins of Adult
Disease—Metabolism
PAS Platform Session
Room 3010-3012, Moscone West
Chairs: William W. Hay and Rebecca A. Simmons
2:00pm–4:00pm
3705—Infections at the
Maternal–Placental–Fetal Interface: Immunopathogenesis of
Group B Streptococcus, Listeria monocytogenes and
Cytomegalovirus
PAS/PIDS Topic Symposium
Room 3022-3024, Moscone West
Chairs: John R. Schreiber, University of Minnesota Medical
School and University of Minnesota Children's
Hospital/Fairview, Minneapolis, MN; and Robert F. Pass,
University of Alabama at Birmingham, Birmingham, AL
Target Audience: Neonatologists,
infectious disease specialists, immunologists, developmental
biologists and general pediatricians.
Infections in newborns commonly
result from acquisition either during the delivery process or
transplacentally. The host and pathogen factors that
contribute to acquisition of infections at the
maternal–placental–fetal interface are poorly understood.
This symposium will review the basic science and
immunopathogenesis of three diverse pathogens that all share
the ability to cause infections at the placental level:
cytomegalovirus, group B streptococcus, and Listeria
monocytogenes.
-
Intrauterine Cytomegalovirus
Infection, Transplacental Spread of Virus and Control by
Maternal Immunity
Lenore Pereira, University of California San Francisco, San Francisco,
CA
-
Host and Bacterial Factors in
Invasive Group B Streptococcal Infection
Craig E. Rubens, University of Washington, Seattle, WA
-
Listeriosis in the Pregnant
Guinea Pig: A Model of Vertical Transmission
Daniel A. Portnoy, University of California Berkeley, Berkeley, CA
-
Discussion
Sponsored jointly by
the Pediatric Infectious Diseases Society and the Pediatric
Academic Societies
2:00pm–4:00pm
3722—Neonatal Lung Inflammation: Mechanisms
and Clinical Implications
PAS Platform Session
Room 3014, Moscone West
Chairs: Rose M. Viscardi and Stephen E. Welty
Supported by an unrestricted educational grant from Dey,
L.P.
2:00pm–4:00pm
3732—Pulmonary and Cardiac Development:
Transcriptional Control and Stem Cells
PAS Platform Session
Room 2004, Moscone West
Chairs: Lawrence M. Nogee and George A. Porter
Includes
-
SPR Student Research Award:
Critical Requirement of C/EBP[alpha] for Lung Maturation
and Funct
Prithy Martis, Cincinnati Children's Hospital Medical Center,
Cincinnati, OH
-
Role of MicroRNAs in
Cardiogenesis
Yong Zhao, Gladstone Institute of Cardiovascular Disease, University of
California San Francisco
2:00pm–5:00pm
3750—Endocrine Disrupters
PAS/LWPES Mini Course
Room 3010-3012, Moscone West
Chairs: Mary M. Lee, University of Massachusetts Medical
School, Worcester, MA; and Henry Anhalt, Saint Barnabas
Medical Center, Livingston, NJ
Target Audience:
Endocrinologists, generalists, neonatologists and basic
scientists.
Concerns regarding clinical
consequences of endocrine disrupting chemicals have increased
over the past decade as researchers have documented
detrimental effects in wildlife. Federal attention to
endocrine disrupters began in earnest in 1996 when the U.S.
Congress passed the Food Quality Protection Act and amended
the Safe Drinking Water Act. These laws mandated testing to
determine if pesticides and industrial chemicals might behave
like hormones; therefore, the U.S. EPA formed the Endocrine
Disrupters Screening and Advisory Committee. In addition to
direct effects, some environmental disrupters act through
non-genomic actions, some of which persist for several
generations. This program presenting innovative studies on
mechanisms of action of endocrine disruptors will be of
critical interest to endocrinologists, both clinical and basic
scientists, as well as public health experts.
-
Prenatal Programming with
Estrogen/Estrogen Mimetics
Kenneth S. Korach, National Institute of Environmental Health Sciences,
Research Triangle Park, NC
-
Epigenetic Transgenerational
Actions of Endocrine Disruptors on Male Fertility and
Other Diseases
Michael K. Skinner, Washington State University, Pullman, WA
-
Prenatal Programming with Native
and Environmental Steroids
Vasantha Padmanabhan, University of Michigan, Ann Arbor, MI
Sponsored jointly by
the Lawson Wilkins Pediatric Endocrine Society and the
Pediatric Academic Societies
4:15pm–5:45pm
3805—Fetal Homeland Security: New Insights
into Old Threats
PAS State of the Art Plenary
Room 3002-3008, Moscone West
Chairs: Phil W. Shaul, University of Texas Southwestern
Medical Center, Dallas, TX; and Rashmin C. Savani, University
of Texas Southwestern Medical Center, Dallas, TX
Target Audience: Neonatologists,
pediatricians and researchers interested in perinatal biology.
In addition to premature birth,
there are a select number of maternal conditions that have
marked negative impact on the well being of the fetus and
newborn. This symposium will highlight recent advances in our
understanding of these classical threats to our most
vulnerable pediatric patient population.
First, new knowledge of the
mechanisms by which maternal diabetes alters embryonic and
fetal development will be discussed. Second, the newly
discovered role of circulating anti-angiogenic proteins of
placental origin in the pathogenesis of preeclampsia will be
presented. Finally, novel mechanisms by which biochemical
events in the fetal lung trigger the initiation of labor will
be discussed. Further advances in each of these realms will
ultimately lead to new therapies to protect the fetus and
yield healthy outcomes at term.
-
Mechanisms by Which Maternal
Diabetes Modifies Embryonic and Fetal Development
Kelle H. Moley, Washington University School of Medicine, St. Louis, MO
-
Role of Circulating Anti-angiogenic
Proteins of Placental Origin in the Pathogenesis of
Preeclampsia
S. Ananth Karumanchi, Harvard Medical School, Beth Isreal Deaconess
Medical Center, Boston, MA
-
Fetal–Maternal Signaling in the
Initiation of Labor
Carole R. Mendelson, University of Texas Southwestern Medical Center,
Dallas, TX
4:15pm–5:45pm
3810—RNA Interference, Technological
Development of siRNAs and Potential Treatments for Childhood
Diseases
PAS State of the Art Plenary
Room 3016-3018, Moscone West
Chair: R. Alan B. Ezekowitz, Harvard Medical School,
Massachusetts General Hospital, Boston, MA
Target Audience: Basic scientists
studying a broad range of childhood diseases, translational
scientists of all disciplines studying clinical implications
of basic science research, clinical scientists studying
childhood and other diseases in need of improved therapies and
clinicians interested in cutting-edge science and its medical
implications.
RNA interference is a recently
discovered, naturally occurring intracellular process that
regulates gene expression through the silencing of specific
mRNAs. Methods of harnessing this natural pathway are being
developed that allow the catalytic degradation of targeted
mRNAs using specifically designed complementary small
inhibitory RNAs (siRNA). siRNAs are being chemically modified
to acquire drug-like properties. Numerous recent high-profile
publications have provided proofs of concept that RNA
interference may be useful therapeutically. Much of the design
of these siRNAs can be accomplished bioinformatically, thus
potentially expediting drug discovery and opening new avenues
of therapy for many childhood diseases including uncommon
pediatric and orphan diseases. A discussion of the science
behind RNA interference will be followed by a presentation of
the potential practical issues in applying this technology to
disease. The program then describes two therapeutic programs
currently under way with applications to pediatric diseases. A
question-and-answer time will follow each discussion.
-
The Science of RNA Interference
John J. Rossi, Beckman Research Institute of City of Hope, Duarte, CA
-
RNA Interference and Its
Potential Applications for Controlling Disease
Judy Lieberman, CBR Institute for Biomedical Research and Harvard
Medical School, Boston, MA
-
Silencing the VEGF Pathway with
siRNAs and the Potential Application to Retinopathy of
Prematurity
Pamela Pavco, Sirna Therapeutics, Boulder, CO
-
siRNA as Therapy for Respiratory
Syncytial Virus
John P. DeVincenzo, University of Tennessee School of Medicine,
Memphis, TN
4:15pm–6:15pm
3865—Neonatal Neurology—Neural Stem Cells
and Neurotrophins
PAS Poster Symposium
Room 3020, Moscone West
Chairs: Sandra E. Juul and Patrick S. McQuillen
Monday,
May 1
8:00am–10:00am
4132—Mechanisms of Neonatal Lung Injury
PAS Platform Session
Room 3003-3005, Moscone West
Chairs: Vineet Bhandari and Vasanth H.S. Kumar
3:00pm–4:00pm
4600A—LWPES Trans-Pacific Lecture
LWPES Award
Room 3002-3008, Moscone West
Chair: Mark Sperling, Children's Hospital of Pittsburgh,
Pittsburgh, PA
Target Audience: Geneticists,
endocrinologists and molecular biologists.
This new lecture recognizes one
outstanding scientist from the Pacific Rim. This talk will
illuminate congenital adrenal disorders with particular focus
on the relationship between newborn screening and molecular
mechanisms.
-
Congenital Adrenal Disorders:
From Newborn Screening to Molecular Mechanism
Kenji Fujieda, Asahikawa Medical College, Asahikawa, Japan
3:00pm–5:00pm
4610—Cardiac Stem Cell Biology and
Therapeutics
PAS Topic Symposium
Room 3001, Moscone West
Chair: Harold S. Bernstein, University of California, San
Francisco, CA
Target Audience: Physicians,
scientists and trainees with interest in pediatric cardiology,
stem cell biology and reparative medicine.
This topic symposium is directed
towards educating interested members about the state of the
art in cardiac stem cell research, both the underlying biology
and initial attempts in animals and humans at cardiac
regenerative therapy. The discussion will range from
hematopoietic stem cells to cardioblasts, as well as to how
one assesses the results of stem cell infusion trials.
-
Recent History of Secondary
Cardiac Myogenesis
Harold S. Bernstein, University of California, San Francisco, CA
-
Mesenchymal Stem-Cell-Based
Cardiac Regeneration
Andrew Boyle, Johns Hopkins University, Baltimore, MD
-
Cardioblasts
Kenneth R. Chien, Mass General Hospital, Harvard Medical School,
Boston, MA
-
Functional Assessment of Myogenic
Stem Cells and Cardiomyocytes for Cardiac Cell Therapy
Loren J. Field, Indiana University School of Medicine, Indianapolis, IN
3:00pm–5:00pm
4630A—Molecular Control of the Formation of
the Renal Collecting System
ASPN Symposium
Room 3010-3012, Moscone West
Chairs: Lisa M. Satlin, Mount Sinai School of Medicine, New
York, NY; and Norman D. Rosenblum, The Hospital for Sick
Children, Toronto, Ontario, Canada
Target Audience: Clinicians,
clinician-scientists and scientists interested in development,
nephrology and human disease involving the urinary tract.
Kidney development depends on
embryonic processes which pattern the collecting system
consisting of the ureter, renal pelvis and calyces, and
collecting ducts. Disruption of these processes in humans
results in a spectrum of anomalies including vesicoureteral
reflux, malformations of the pelvis and calyces, a decreased
number of collecting ducts and cystic malformation of these
ducts. Presentations in this symposium will highlight newly
elucidated genetic mechanisms that control different aspects
of collecting system formation. Analyses of genetic mouse
models are demonstrating a critical role for Fibroblast Growth
Factor Receptors in controlling growth and branching of the
ureteric buds that give rise to collecting ducts. Recent
evidence reveals a critical role for HNF1b, a transcription
factor, in controlling collecting duct terminal
differentiation and cyst formation via mechanisms involving
PKDH1, the gene mutated in human autosomal recessive kidney
disease. New genetic approaches are being harnessed to define
molecular mechanisms that control formation of the
vesico-ureteric orifice. Together, these discoveries and
approaches are providing novel molecular insights into
developmental nephrology and human disease.
-
Overview
Norman D. Rosenblum, Professor of Paediatrics and Canada Research Chair
in Developmental Nephrology, Division of Nephrology &
Program in Developmental Biology, The Hospital for Sick
Children, Toronto, Ontario, Canada
-
Role of Fibroblast Growth Factor
Receptors in Kidney Development
Carlton M. Bates, Children's Hospital of Columbus, Columbus, OH
-
Transcriptional Control of the
Bradykinin B2 Receptor
Samir S. El-Dahr, Tulane University School of Medicine, New Orleans, LA
-
Roles of HNF-1beta in Kidney
Development and Disease
Peter Igarashi, University of Texas Southwestern School of Medicine,
Dallas, TX
-
Genes and VUR
Ali Gharavi, Columbia University, New York, NY
3:00pm–5:00pm
4670—Brain Metabolism and Injury
PAS Platform Session
Room 3020, Moscone West
Chairs: Steven P. Miller and Frances J. Northington
Includes
-
SPR Fellow's Basic Research
Award: The Neuron-Glia Lactate Shuttle Protects
Neurological Function in Neuron-Specific Glucose
Deficiency
Camille Fung, David Geffen School of Medicine at UCLA, Los Angeles, CA
Tuesday,
May 2
8:00am–10:00am
5150—Cardiology—Genetics and Development
PAS Platform Session
Room 3000, Moscone West
Chairs: H. Scott Baldwin and Marlene Rabinovitch
Includes
-
SPR Student Research Award:
Mutations in [italic]JPH2-[/italic]Encoded Junctophilin 2
as a Novel Pathogenic Mechanism in Hypertrophic
Cardiomyopathy
Karin Batalden, Mayo Medical School, College of Medicine, Rochester, MN
8:00am–10:00am
5166—Lung Development and Alveolarization
PAS Poster Symposium
Room 3003-3005, Moscone West
Chairs: Lawrence S. Prince and A. Keith Tanswell
Includes
8:00am–10:00am
5168—Oxidants, Antioxidants and the Battles
They Wage
PAS Poster Symposium
Room 3014, Moscone West
Chairs: Jonathan M. Davis and Charles V. Smith
8:30am–9:45am
5200A—The Challenge of Diagnosis and
Outcome in Intersex
LWPES State of the Art Plenary
Room 3007-3011, Moscone West
Chair: Lynne Levitsky, Massachusetts General Hospital, Boston,
MA
Target Audience: Geneticists,
endocrinologists and general pediatricians.
The attendee will be presented
with an overview of intersex and then the challenges of
diagnosis and outcome will be addressed. Many previous
assumptions about outcome have proven to be false. This should
prove to be an exciting talk about a highly controversial
topic affecting pediatric endocrinologists and geneticists.
The Challenge of Diagnosis and
Outcome in Intersex
Ieuan Hughes, University of Cambridge, Cambridge, UK
10:15am–12:15pm
5435—Endocrinology and Diabetes—Basic
Research
PAS/LWPES Platform Session
Room 3007-3011, Moscone West
Chairs: Stephen E. Gitelman and Anna Spagnoli
1:45pm–3:45pm
5720—Autosomal Recessive Polycystic Kidney
Disease (ARPKD): New Insights and Clinical Perspectives
PAS/ASPN/NASPGHAN Topic Symposium
Room 3010-3012, Moscone West
Chairs: Philip Rosenthal, University of California, San
Francisco, San Francisco, CA; and Lisa M. Guay-Woodford,
University of Alabama at Birmingham, Birmingham, AL
Target Audience: Pediatricians,
pediatric nephrologists, pediatric gastroenterologists,
neonatalogists and developmental biologists.
ARPKD is a developmental disorder
of the kidneys and liver caused by mutations in the PKHD1
gene. Fibrocystin/polyductin, the protein encoded by PKHD1, is
expressed on the primary cilia of renal and bile duct
epithelial cells. Several lines of evidence indicate that the
PKHD1 transcriptional profile is complex with extensive splice
variants. While the function of these transcripts and the
polypeptides that they encode is not well understood, these
proteins seem to play critical roles in establishing and
maintaining the tubular architecture. This symposium will
discuss the complex transcriptional profile of PKHD1 and the
role of these gene products in renal as well as biliary
epithelia. Given that ARPKD has a high perinatal mortality due
to oligohydramnios and resultant respiratory insufficiency,
current concepts regarding the interplay between the
developing kidney, the placenta and the developing lung will
be discussed. Finally, a clinical perspective based on the
on-going NHGRI-sponsored natural history study will focus on
ARPKD-associated morbidities and disease progression.
-
Transcriptional Complexity of
PKHD1: Implications for Development and Disease
Pathogenesis
Gregory G. Germino, Johns Hopkins University, Baltimore, MD
-
Pathobiology of Biliary Epithelia
in ARPKD
Tatyana Masyuk, Mayo Clinic College of Medicine, Rochester, MN
-
Oligohydramnios: Current Concepts
and Implications for Pulmonary Development
F. Sessions Cole, Washington University School of Medicine, St. Louis
Children's Hospital, St. Louis, MO
-
Report on the NIH ARPKD/CHF
Natural History Study
Meral Gunay-Aygun, National Human Genome Research Institute (NHGRI),
Bethesda, MD
Sponsored jointly by
the American Society of Pediatric Nephrology; the North
American Society for Pediatric Gastroenterology, Hepatology
and Nutrition; and the Pediatric Academic Societies
1:45pm–3:45pm
5755—Neonatal Brain Injury: How Can We Do
More Good Than Harm?
PAS Platform Session
Room 3003-3005, Moscone West
Chairs: Sylvain Chemtob and Augusto Sola
|
